Terms: = Kidney tumors AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
28 results:
1. Inhibition of Cyclin F Promotes Cellular Senescence through Cyclin-dependent Kinase 1-mediated Cell Cycle Regulation.
Li X; Li YJ; Wang MJ; Ou KP; Chen YQ
Curr Med Sci; 2023 Apr; 43(2):246-254. PubMed ID: 36602672
[TBL] [Abstract] [Full Text] [Related]
2. The amount of DNA combined with tp53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
Del Re M; Crucitta S; Paolieri F; Cucchiara F; Verzoni E; Bloise F; Ciampi R; Mercinelli C; Capuano A; Sportiello L; Martinetti A; Procopio G; Galli L; Porta C; Bracarda S; Danesi R
J Transl Med; 2022 Aug; 20(1):371. PubMed ID: 35974365
[TBL] [Abstract] [Full Text] [Related]
3. p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics.
Diesing K; Ribback S; Winter S; Gellert M; Oster AM; Stühler V; Gläser E; Adler F; Hartwig C; Scharpf M; Bedke J; Burchardt M; Schwab M; Lillig CH; Kroeger N
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3565-3576. PubMed ID: 34499221
[TBL] [Abstract] [Full Text] [Related]
4. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract] [Full Text] [Related]
5. Renal Epithelioid Angiomyolipoma Undergoing Aggressive clinical outcome: The MDM2 Expression in Tumor Cells of Two Cases.
Inoue C; Saito R; Nakanishi W; Kumata H; Eba S; Fujishima F; Watanabe M; Sasano H
Tohoku J Exp Med; 2019 Feb; 247(2):119-127. PubMed ID: 30799331
[TBL] [Abstract] [Full Text] [Related]
6. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract] [Full Text] [Related]
7. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract] [Full Text] [Related]
8. Characterizing clinicopathological findings of transarterial chemoembolization for Wilms tumor.
Li JP; Chu JP; Oh P; Li Z; Chen W; Huang YH; Yang JY
J Urol; 2010 Mar; 183(3):1138-44. PubMed ID: 20096886
[TBL] [Abstract] [Full Text] [Related]
9. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of gene expression profiles in tubulocystic carcinoma and collecting duct carcinoma of the kidney.
Osunkoya AO; Young AN; Wang W; Netto GJ; Epstein JI
Am J Surg Pathol; 2009 Jul; 33(7):1103-6. PubMed ID: 19390420
[TBL] [Abstract] [Full Text] [Related]
11. Global levels of histone modifications predict prognosis in different cancers.
Seligson DB; Horvath S; McBrian MA; Mah V; Yu H; Tze S; Wang Q; Chia D; Goodglick L; Kurdistani SK
Am J Pathol; 2009 May; 174(5):1619-28. PubMed ID: 19349354
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract.
Jeong IG; Kim SH; Jeon HG; Kim BH; Moon KC; Lee SE; Lee E
Hum Pathol; 2009 May; 40(5):668-77. PubMed ID: 19157504
[TBL] [Abstract] [Full Text] [Related]
13. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype.
Christoph F; Hinz S; Kempkensteffen C; Schostak M; Schrader M; Miller K
J Urol; 2007 Dec; 178(6):2655-9. PubMed ID: 17945286
[TBL] [Abstract] [Full Text] [Related]
14. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Köllermann J; Miller K; Schrader M
Clin Cancer Res; 2006 Sep; 12(17):5040-6. PubMed ID: 16951219
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic biomarkers in renal cell carcinoma: relevance of DNA ploidy in predicting disease-related survival.
Pinto AE; Monteiro P; Silva G; Ayres JV; Soares J
Int J Biol Markers; 2005; 20(4):249-56. PubMed ID: 16398407
[TBL] [Abstract] [Full Text] [Related]
16. The pT1a and pT1b category subdivision in renal cell carcinoma: is it reflected by differences in tumour biology?
Langner C; Ratschek M; Rehak P; Tsybrovskyy O; Zigeuner R
BJU Int; 2005 Feb; 95(3):310-4. PubMed ID: 15679784
[TBL] [Abstract] [Full Text] [Related]
17. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors.
Lee CT; Genega EM; Hutchinson B; Fearn PA; Kattan MW; Russo P; Reuter VE
Urol Oncol; 2003; 21(3):179-84. PubMed ID: 12810203
[TBL] [Abstract] [Full Text] [Related]
18. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract.
Nakanishi K; Tominaga S; Hiroi S; Kawai T; Aida S; Kasamatsu H; Aurues T; Hayashi T; Ikeda T
Virchows Arch; 2002 Dec; 441(6):559-63. PubMed ID: 12461612
[TBL] [Abstract] [Full Text] [Related]
19. clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma.
Uchida T; Gao JP; Wang C; Jiang SX; Muramoto M; Satoh T; Minei S; Shimura S; Irie A; Kameya T; Baba S
Urology; 2002 Apr; 59(4):615-20. PubMed ID: 11927338
[TBL] [Abstract] [Full Text] [Related]
20. Chromosome 9 and 17 aberrations and p53 gene deletion detected by fluorescence in situ hybridization in renal-cell carcinoma.
Yoshioka K; Nakamura S
Mol Urol; 2001; 5(1):11-7. PubMed ID: 11689146
[TBL] [Abstract] [Full Text] [Related]
[Next]
